Breast Cancer Research and Treatment

, Volume 121, Issue 2, pp 355–364

A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels

  • Christine M. Stellrecht
  • Mary Ayres
  • Rishi Arya
  • Varsha Gandhi
Preclinical study

Abstract

In contrast to deoxyribose or arabinose containing nucleoside analogs that are currently established for cancer therapeutics, 8-chloro-adenosine (8-Cl-Ado) possesses a ribose sugar. This unique nucleoside analog is RNA-directed and is in a phase I clinical trial for hematological malignancies. RNA-directed therapies are effective for the treatment of many malignancies as their activities are primarily aimed at short-lived transcripts, which are typically encoded by genes that promote the growth and survival of tumor cells such as cyclin E in breast cancer. Based on this, we hypothesized that 8-Cl-Ado, a transcription inhibitor, will be effective for the treatment of breast cancer cells. The metabolism of 8-Cl-Ado and the effect on ATP in the breast cancer cell lines MCF-7 and BT-474 were measured using HPLC analysis. In these cells, 8-Cl-Ado was effectively taken up, converted to its cytotoxic metabolite, 8-Cl-ATP, and depleted the endogenous ATP levels. This in turn led to an inhibition of RNA synthesis. The RNA synthesis inhibition was associated with a depletion of cyclin E expression, which is indicative of a diminished tumorigenic phenotype. The final outcome of 8-Cl-Ado treatment of the breast cancer cells was growth inhibition due to an induction of apoptosis and a loss of clonogenic survival. These results indicate that 8-Cl-Ado, which is currently in clinic for hematological malignancies, may be an effective agent for the treatment of breast cancer.

Keywords

8-chloro-adenosine Breast cancer Nucleoside analog RNA synthesis inhibition Cyclin E 

References

  1. 1.
    Stellrecht CM, Chen LS, Gandhi V (2005) Inhibition of oncogene expression by RNA-directed agents. In: Gandhi V (ed) Transcription as a target for cancer therapeutics AACR educational book. American Association for Cancer Research, Philadelphia, pp 338–343Google Scholar
  2. 2.
    Derheimer FA, Chang CW, Ljungman M (2005) Transcription inhibition: a potential strategy for cancer therapeutics. Eur J Cancer 41:2569–2576CrossRefPubMedGoogle Scholar
  3. 3.
    Bakheet T, Williams BR, Khabar KS (2003) ARED 2.0: an update of AU-rich element mRNA database. Nucleic Acids Res 31:421–423CrossRefPubMedGoogle Scholar
  4. 4.
    Lam LT, Pickeral OK, Peng AC et al. (2001) Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2:research0041.0041-research0041.0011Google Scholar
  5. 5.
    Weinstein IB (2002) Addiction to oncogenes–the Achilles heal of cancer. Science 297:63–64CrossRefPubMedGoogle Scholar
  6. 6.
    Weinstein IB, Joe A (2008) Oncogene addiction. Cancer Res 68:3077–3080CrossRefPubMedGoogle Scholar
  7. 7.
    Weinstein B (2008) Relevance of the concept of oncogene addiction to hormonal carcinogenesis and molecular targeting in cancer prevention and therapy. Adv Exp Med Biol 617:3–13CrossRefPubMedGoogle Scholar
  8. 8.
    Certo M, Moore Vdel G, Nishino M et al (2006) Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9:351–365CrossRefPubMedGoogle Scholar
  9. 9.
    Chen R, Wierda WG, Chubb S et al (2009) Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 113:4637–4645. doi:10.1182/blood-2008-12-190256 CrossRefPubMedGoogle Scholar
  10. 10.
    Chen R, Keating MJ, Gandhi V, Plunkett W (2005) Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 106:2513–2519CrossRefPubMedGoogle Scholar
  11. 11.
    Gojo I, Zhang B, Fenton RG (2002) The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 8:3527–3538PubMedGoogle Scholar
  12. 12.
    Pepper C, Thomas A, Hoy T, Fegan C, Bentley P (2001) Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. Br J Haematol 114:70–77CrossRefPubMedGoogle Scholar
  13. 13.
    Phillip CJ, Stellrecht CM, Nimmanapalli R, Gandhi V (2009) Targeting MET transcription as a therapeutic strategy in multiple myeloma. Cancer Chemother Pharmacol 63:587–597. doi:10.1007/s00280-008-0770-2 CrossRefPubMedGoogle Scholar
  14. 14.
    Raje N, Kumar S, Hideshima T et al (2005) Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 106:1042–1047CrossRefPubMedGoogle Scholar
  15. 15.
    MacCallum DE, Melville J, Frame S et al (2005) Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 65:5399–5407CrossRefPubMedGoogle Scholar
  16. 16.
    Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24:1770–1783CrossRefPubMedGoogle Scholar
  17. 17.
    Balakrishnan K, Stellrecht CM, Genini D et al (2005) Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP. Blood 105:4455–4462. doi:10.1182/blood-2004-05-1699 CrossRefPubMedGoogle Scholar
  18. 18.
    Langeveld CH, Jongenelen CA, Theeuwes JW et al (1997) The antiproliferative effect of 8-chloro-adenosine, an active metabolite of 8-chloro-cyclic adenosine monophosphate, and disturbances in nucleic acid synthesis and cell cycle kinetics. Biochem Pharmacol 53:141–148. doi:S0006-2952(96)00593-X[pii] CrossRefPubMedGoogle Scholar
  19. 19.
    Langeveld CH, Jongenelen CA, Heimans JJ, Stoof JC (1992) 8-Chloro-cyclic adenosine monophosphate, a novel cyclic AMP analog that inhibits human glioma cell growth in concentrations that do not induce differentiation. Exp Neurol 117:196–203. doi:0014-4886(92)90127-C[pii] CrossRefPubMedGoogle Scholar
  20. 20.
    Langeveld CH, Jongenelen CA, Heimans JJ, Stoof JC (1992) Growth inhibition of human glioma cells induced by 8-chloroadenosine, an active metabolite of 8-chloro cyclic adenosine 3′:5′-monophosphate. Cancer Res 52:3994–3999PubMedGoogle Scholar
  21. 21.
    Gandhi V, Ayres M, Halgren RG et al (2001) 8-chloro-cAMP and 8-chloro-adenosine act by the same mechanism in multiple myeloma cells. Cancer Res 61:5474–5479PubMedGoogle Scholar
  22. 22.
    Krett NL, Zell JL, Halgren RG et al (1997) Cyclic adenosine-3′, 5′-monophosphate-mediated cytotoxicity in steroid sensitive and resistant myeloma. Clin Cancer Res 3:1781–1787PubMedGoogle Scholar
  23. 23.
    Halgren RG, Traynor AE, Pillay S et al (1998) 8Cl-cAMP cytotoxicity in both steroid sensitive and insensitive multiple myeloma cell lines is mediated by 8Cl-adenosine. Blood 92:2893–2898PubMedGoogle Scholar
  24. 24.
    Zhu B, Zhang LH, Zhao YM, Cui JR, Strada SJ (2006) 8-chloroadenosine induced HL-60 cell growth inhibition, differentiation, and G(0)/G(1) arrest involves attenuated cyclin D1 and telomerase and up-regulated p21(WAF1/CIP1). J Cell Biochem 97:166–177CrossRefPubMedGoogle Scholar
  25. 25.
    Carlson CC, Chinery R, Burnham LL, Dransfield DT (2000) 8-Cl-adenosine-induced inhibition of colorectal cancer growth in vitro and in vivo. Neoplasia 2:441–448CrossRefPubMedGoogle Scholar
  26. 26.
    Zhang HY, Gu YY, Li ZG et al (2004) Exposure of human lung cancer cells to 8-chloro-adenosine induces G2/M arrest and mitotic catastrophe. Neoplasia 6:802–812CrossRefPubMedGoogle Scholar
  27. 27.
    Stellrecht CM, Rodriguez CO Jr, Ayres M, Gandhi V (2003) RNA-directed actions of 8-chloro-adenosine in multiple myeloma cells. Cancer Res 63:7968–7974PubMedGoogle Scholar
  28. 28.
    Chen LS, Sheppard TL (2004) Chain termination and inhibition of Saccharomyces cerevisiae poly(A) polymerase by C-8-modified ATP analogs. J Biol Chem 279:40405–40411CrossRefPubMedGoogle Scholar
  29. 29.
    Stellrecht CM, Phillip CJ, Cervantes-Gomez F, Gandhi V (2007) Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase. Cancer Res 67:9913–9920. doi:10.1158/0008-5472.CAN-07-0770 CrossRefPubMedGoogle Scholar
  30. 30.
    Keyomarsi K, Pardee AB (1993) Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A 90:1112–1116CrossRefPubMedGoogle Scholar
  31. 31.
    Keyomarsi K, O’Leary N, Molnar G et al (1994) Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 54:380–385PubMedGoogle Scholar
  32. 32.
    Reed SI (2005) Deregulation of cyclin E in cancer. In: Reed SI (ed) The ubiquitin proteasome system: roles and targets in cancer AACR educational book. American Association for Cancer Research, Philadelphia, pp 53–56Google Scholar
  33. 33.
    Keck JM, Summers MK, Tedesco D et al (2007) Cyclin E overexpression impairs progression through mitosis by inhibiting APCCdh1. J Cell Biol 178:371–385CrossRefPubMedGoogle Scholar
  34. 34.
    Akli S, Zheng PJ, Multani AS et al (2004) Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 64:3198–3208CrossRefPubMedGoogle Scholar
  35. 35.
    Ekholm-Reed S, Mendez J, Tedesco D et al (2004) Deregulation of cyclin E in human cells interferes with prereplication complex assembly. J Cell Biol 165:789–800CrossRefPubMedGoogle Scholar
  36. 36.
    Bagheri-Yarmand R, Keyomarsi K (2009) Overexpression of full length or low molecular weight of cyclin E leads to differential G2/M transition and mitotic defects through deregulation of cdc25c. AACR Meet Abstr 2009:2473Google Scholar
  37. 37.
    Keyomarsi K, Tucker SL, Buchholz TA et al (2002) Cyclin E and survival in patients with breast cancer. N Engl J Med 347:1566–1575CrossRefPubMedGoogle Scholar
  38. 38.
    Sieuwerts AM, Look MP, Meijer-van Gelder ME et al (2006) Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. Clin Cancer Res 12:3319–3328CrossRefPubMedGoogle Scholar
  39. 39.
    Keyomarsi K, Tucker SL, Bedrosian I (2003) Cyclin E is a more powerful predictor of breast cancer outcome than proliferation. Nat Med 9:152CrossRefPubMedGoogle Scholar
  40. 40.
    Wingate H, Bedrosian I, Akli S, Keyomarsi K (2003) The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. Cell cycle 2:461–466PubMedGoogle Scholar
  41. 41.
    Wingate H, Zhang N, McGarhen MJ et al (2005) The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. J Biol Chem 280:15148–15157CrossRefPubMedGoogle Scholar
  42. 42.
    Akli S, Van Pelt CS, Bui T et al (2007) Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res 67:7212–7222CrossRefPubMedGoogle Scholar
  43. 43.
    Clurman BE, Sheaff RJ, Thress K, Groudine M, Roberts JM (1996) Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev 10:1979–1990CrossRefPubMedGoogle Scholar
  44. 44.
    Hapke DM, Stegmann AP, Mitchell BS (1996) Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res 56:2343–2347PubMedGoogle Scholar
  45. 45.
    Arner ES, Eriksson S (1995) Mammalian deoxyribonucleoside kinases. Pharmacol Ther 67:155–186CrossRefPubMedGoogle Scholar
  46. 46.
    Shedden K, Townsend LB, Drach JC, Rosania GR (2003) A rational approach to personalized anticancer therapy: chemoinformatic analysis reveals mechanistic gene-drug associations. Pharm Res 20:843–847CrossRefPubMedGoogle Scholar
  47. 47.
    Carlson CC, Burnham LL, Shanks RA, Dransfield DT (2001) 8-Cl-adenosine induces differentiation in LS174T cells. Dig Dis Sci 46:757–764CrossRefPubMedGoogle Scholar
  48. 48.
    Van Lookeren Campagne MM, Villalba Diaz F, Jastorff B, Kessin RH (1991) 8-Chloroadenosine 3′, 5′-monophosphate inhibits the growth of Chinese hamster ovary and Molt-4 cells through its adenosine metabolite. Cancer Res 51:1600–1605PubMedGoogle Scholar
  49. 49.
    Lu X, Errington J, Chen VJ et al (2001) Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines. Clin Cancer Res 6:271–277Google Scholar
  50. 50.
    Jang JY, Choi Y, Jeon YK, Kim CW (2008) Suppression of adenine nucleotide translocase-2 by vector-based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivo. Breast Cancer Res 10:R11CrossRefPubMedGoogle Scholar
  51. 51.
    Akli S, Keyomarsi K (2003) Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biol Ther 2:S38–S47PubMedGoogle Scholar
  52. 52.
    Spruck CH, Won KA, Reed SI (1999) Deregulated cyclin E induces chromosome instability. Nature 401:297–300CrossRefPubMedGoogle Scholar
  53. 53.
    Ma Y, Fiering S, Black C et al (2007) Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci U S A 104:4089–4094CrossRefPubMedGoogle Scholar
  54. 54.
    Sgambato A, Camerini A, Pani G et al (2003) Increased expression of cyclin E is associated with an increased resistance to doxorubicin in rat fibroblasts. Br J Cancer 88:1956–1962CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • Christine M. Stellrecht
    • 1
  • Mary Ayres
    • 1
  • Rishi Arya
    • 1
  • Varsha Gandhi
    • 1
    • 2
  1. 1.Department of Experimental TherapeuticsUniversity of Texas M.D. Anderson Cancer CenterHoustonUSA
  2. 2.Department of LeukemiaUniversity of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations